Nanoscope Therapeutics
Biotechnology, 1312 Brown TRL Ste A, Dallas, Texas, 76022, United States, 11-50 Employees
Phone Number: 18*********
Who is NANOSCOPE THERAPEUTICS
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from reti...
Read More
-
Headquarters: 1312 Brown TRL Ste A, Dallas, Texas, 76022, United States
-
Date Founded: 2017
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from NANOSCOPE THERAPEUTICS
Nanoscope Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Nanoscope Therapeutics
Answer: Nanoscope Therapeutics's headquarters are located at 1312 Brown TRL Ste A, Dallas, Texas, 76022, United States
Answer: Nanoscope Therapeutics's phone number is 18*********
Answer: Nanoscope Therapeutics's official website is https://nanostherapeutics.com
Answer: Nanoscope Therapeutics's revenue is $1 Million to $5 Million
Answer: Nanoscope Therapeutics's SIC: 8731
Answer: Nanoscope Therapeutics has 11-50 employees
Answer: Nanoscope Therapeutics is in Biotechnology
Answer: Nanoscope Therapeutics contact info: Phone number: 18********* Website: https://nanostherapeutics.com
Answer: Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscopes proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month